Tildrakizumab-Asmn (Ilumya™)

Ilumya (tildrakizumab-asmn) is covered for adults ≥18 with FDA‑approved moderate-to-severe plaque psoriasis (pediatric <18 excluded), dosed per label (100 mg SC at weeks 0 and 4 then every 12 weeks) with initial approval for 3 months and renewals for 12 months. Initial authorization requires a documented 3‑month trial or intolerance to at least one biologic or traditional systemic agent (or methotrexate contraindication) and dermatologist prescribing/consultation; reauthorization requires ≥90 days on Ilumya with objective clinical improvement (BSA, erythema/induration/scale) and symptom improvement (e.g., itching, pain).

"Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.